Oncternal Therapeutics (ONCT)
(Delayed Data from NSDQ)
$4.95 USD
+0.10 (2.04%)
Updated Aug 23, 2024 03:48 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Oncternal Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -39.48 | -44.17 | -31.33 | -17.23 | -34.19 |
Depreciation/Amortization & Depletion | -1.63 | -0.08 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 1.27 | -0.07 | -1.30 | -1.68 | -2.51 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.67 | 7.61 | 6.04 | 1.41 | 19.96 |
Net Cash From Operating Activities | -32.16 | -36.70 | -26.59 | -17.50 | -16.75 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | -2.16 |
Investments | 0.65 | -26.50 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 18.29 |
Net Cash from Investing Activities | 0.65 | -26.50 | 0.00 | 0.00 | 16.14 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.07 | 9.58 | 0.62 | 113.88 | 0.02 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 |
Net Cash from Financing Activities | 1.07 | 9.58 | 0.62 | 114.18 | 0.02 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -30.45 | -53.62 | -25.97 | 96.69 | -0.59 |
Cash at Beginning of Period | 37.14 | 90.77 | 116.74 | 20.05 | 20.65 |
Cash at End of Period | 6.70 | 37.14 | 90.77 | 116.74 | 20.05 |
Diluted Net EPS | -13.43 | -16.80 | -12.80 | -17.00 | -66.20 |
Fiscal Year End for Oncternal Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -16.95 | -8.39 | -39.48 | -30.32 | -20.45 |
Depreciation/Amortization & Depletion | -0.53 | -0.31 | -1.63 | -1.27 | -0.91 |
Net Change from Assets/Liabilities | 1.40 | -0.14 | 1.27 | 0.41 | -2.51 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.81 | 1.39 | 7.67 | 5.43 | 3.64 |
Net Cash From Operating Activities | -13.26 | -7.44 | -32.16 | -25.75 | -20.23 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 13.03 | 7.22 | 0.65 | 2.46 | -2.20 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 13.03 | 7.22 | 0.65 | 2.46 | -2.20 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -0.09 | -0.09 | 1.07 | 1.07 | 1.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -0.09 | -0.09 | 1.07 | 1.07 | 1.12 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.32 | -0.30 | -30.45 | -22.22 | -21.31 |
Cash at Beginning of Period | 6.70 | 6.70 | 37.14 | 37.14 | 37.14 |
Cash at End of Period | 6.38 | 6.40 | 6.70 | 14.93 | 15.83 |
Diluted Net EPS | -2.89 | -2.83 | -3.03 | -3.40 | -3.00 |